 MedPage Today | Novartis heart failure candidate clears phase III trial PMLiVE The RELAX-AHF study compared serelaxin (RLX030) to placebo in patients with acute heart failure over six months, and found that Novartis' drug was effective both in reducing all-cause mortality and also improved symptoms. The results – released ahead ... Heart Failure Drug Promising in Phase III Trial Novartis Phase III study in acute heart failure Novartis's drug reduces heart failure deaths: study |
